Cardano Risk Management B.V. Invests $96.66 Million in Amgen Inc. $AMGN

Cardano Risk Management B.V. purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 274,717 shares of the medical research company’s stock, valued at approximately $96,659,000. Cardano Risk Management B.V. owned 0.05% of Amgen as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Anfield Capital Management LLC increased its stake in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC lifted its stake in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the period. Board of the Pension Protection Fund acquired a new stake in shares of Amgen in the 4th quarter worth approximately $26,000. Manning & Napier Advisors LLC boosted its holdings in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC bought a new position in shares of Amgen in the fourth quarter valued at approximately $33,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on AMGN. Royal Bank Of Canada reiterated a “positive” rating on shares of Amgen in a research note on Thursday, June 18th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research note on Thursday, June 18th. Erste Group Bank reiterated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Canaccord Genuity Group started coverage on Amgen in a research note on Monday, April 20th. They issued a “hold” rating and a $366.00 price objective on the stock. Finally, Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $354.42.

Amgen Stock Up 1.3%

NASDAQ AMGN opened at $351.64 on Thursday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The company’s 50 day simple moving average is $340.45 and its 200 day simple moving average is $345.95. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29. The company has a market capitalization of $189.78 billion, a P/E ratio of 24.47, a PEG ratio of 3.48 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts expect that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.